Unlocking the human inner ear for therapeutic intervention

Hao Li1, Sumit Agrawal2,3,4, Seyed Alireza Rohani2, Ning Zhu6,7, Daniela I. Cacciabue8, Marcelo N. Rivolta8,14, Douglas E. H. Hartley9,10,11,14, Dan Jiang12,13,14, Hanif M. Ladak2,3,4,5,14,15, Gerard M. O’Donoghue9,10,14,15 & Helge Rask-Andersen1,14,15

The human inner ear contains minute three-dimensional neurosensory structures that are deeply embedded within the skull base, rendering them relatively inaccessible to regenerative therapies for hearing loss. Here we provide a detailed characterisation of the functional architecture of the space that hosts the cell bodies of the auditory nerve to make them safely accessible for the first time for therapeutic intervention. We used synchrotron phase-contrast imaging which offers the required microscopic soft-tissue contrast definition while simultaneously displaying precise bony anatomic detail. Using volume-rendering software we constructed highly accurate 3-dimensional representations of the inner ear. The cell bodies are arranged in a bony helical canal that spirals from the base of the cochlea to its apex; the canal volume is 1.6 μL but with a diffusion potential of 15 μL. Modelling data from 10 temporal bones enabled definition of a safe trajectory for therapeutic access while preserving the cochlea’s internal architecture. We validated the approach through surgical simulation, anatomical dissection and micro-radiographic analysis. These findings will facilitate future clinical trials of novel therapeutic interventions to restore hearing.

By 2050, disabling hearing loss due to damage to the sensorineural structures of the inner ear will affect over 700 million individuals globally with major health, economic and societal implications1. Yet no biological treatment exists for this disabling condition. Auditory prostheses, such as hearing aids and cochlear implants, represent the mainstay of current management but have considerable functional limitations. The greatest challenge today is to find a curative treatment for hearing loss through restoration of the neurosensory substrates that underpin our ability to hear. This challenge is formidable as the human cochlea is a highly specialised post-mitotic organ with highly restricted proliferative and regenerative capabilities. The cochlea’s sensory receptors comprise vibration-sensitive hair cells, their synapses and the neurones that subserve them. The system is exquisitely finetuned, and can respond within milliseconds to a second to displacement of atomic dimensions. These neurosensory structures are fragile and may be permanently lost due to genetic and environmental factors and are particularly susceptible to the ageing process. The hearing loss may be due to a loss of hair cells2, synaptic dysfunction3 or to depletion of the neural population within the cochlea4 as well as a dysfunction of the stria vascularis and fibrocyte network5. The alarming rise in prevalence of hearing loss, now affecting 7% of the world’s population, is a major stimulus to exploit the potential of regenerative medicine in this field6.

Hampering progress has been the inaccessibility of the human cochlea which lies in the skull base deeply encased in the hardest bone in the human body. Yet, once accessed, the cochlea promises to be a receptive organ for neurosensory regeneration: the neurosensory cells are relatively few in number and its minute fluid
cochlear tissues are relatively immune-privileged being protected by the blood-labyrinth barrier thus dampening the inflammatory rejection process. Recent elaboration of a range of molecular mechanisms responsible for inner ear dysfunction have opened a vista of opportunities for a range of novel therapeutic approaches to hearing loss including small molecules, gene and cell therapies. Central to success, however, is the ability to deliver these agents safely and precisely to their target structures within the relatively impenetrable human cochlea. Encouraging evidence from non-human mammalian studies have shown that targeted administration of human stem cell-derived otic progenitors can result in hearing restoration. To exert their therapeutic effects, otic progenitors and the pathways of nerves to be tracked through to the bony core (or modiolus) of the cochlea. This level of detail subsequently informed the planning of a safe surgical approach for clinical application.

Results

Rosenthal's canal (RC), which houses the cell bodies of the 30 to 35,000 human spiral ganglion (HSG) neurons of the auditory nerve, hugs the modiolus and extends from its base to near the cochlear apex (Fig. 1). The physical characteristics of RC are described in Table 1 (and Supplementary Table 1). Our analysis determined that it averages 14.57 mm in length (range 14.02–15.08 mm) and that it is covered by bone with a thickness of 25–56 µm which may be deficient in parts. The diameter of RC varies from 0.1 to 0.5 mm, being at its greatest towards the apex of the helix and has an average volume of 1.6 mm³ (Supplementary Fig. 2). The central projections of the auditory nerve traverse a virtual space containing cerebrospinal fluid as they exit the cochlea on their way to the brain-stem (Supplementary Fig. 3). We calculated this space to have a potential volume of 15 mm³ and as these nerve fibres are devoid of perineurium and may thus be receptive to cell or gene-based therapies.

Fortunately, at the base of the cochlea the RC lies in close proximity to the round window membrane (Fig. 1 and Supplementary Fig. 4), a structure that is easily identifiable during routine ear surgery and that can be readily penetrated or reflected to gain access to RC. We thus used synchrotron radiation phase-contrast imaging (SR-PCI) to delineate these minute structures while leaving them in situ. Several synchrotron studies applied to the inner ear have been published recently, but here we have greatly extended this work to define and validate a novel therapeutic corridor to the human inner ear. SR-PCI differs from conventional radiography in being able to allow a phase shifted beam to interact with the original beam to produce fringes that represent the structural and surface boundaries (edge enhancement) of a specimen. This phase-contrast imaging produces images with excellent soft-tissue and bone discrimination and made it possible to accurately image the detailed cytoarchitecture of the human inner ear, in particular to access the structures that harbour the cochlear neurons in the intact state without incurring artefacts that so compromised previous anatomical studies.

The use of advanced computer vision tools enabled fine blood vessels to be imaged and the pathways of nerves to be tracked through to the bony core (or modiolus) of the cochlea. This level of detail subsequently informed the planning of a safe surgical approach for clinical application.

Discussion

The inability to adequately image the fine structures of the human inner ear has been a major barrier to advance therapies for this complex end-organ. SR-PCI is proving to be transformative in displaying and evaluating these microscopic structures providing unprecedented visualisation of its in-situ cytoarchitecture. Traditional methods used to design surgical routes to the cochlea, even with operating microscopes, were mired by their inherent destructive nature. We have demonstrated, that 3-dimensional models based on SR-PCI data allow the
conception of highly accurate intervention pathways which were subsequently validated by anatomical dissection
and micro-radiographic imaging. These findings will greatly facilitate the accurate delivery of novel therapeutic
agents to their target structures in the inner ear and will thus derisk future clinical trials. The application of SR-
PCI to the auditory system also dovetails with an escalation of interest in regenerative inner ear therapies which
hold considerable promise for addressing the growing health burden of hearing loss14–16. While considerable
challenges remain in developing novel therapeutics for use in humans17, we believe that these developments
herald a new era for the application of regenerative therapeutics to the inner ear. Although SR-PCI cannot be
used in humans in vivo its translational value is immense through enabling precise modelling of the inner ear
microstructures to guide therapeutic access. These models can be further enhanced by automatic segmentation
and deep-learning networks to improve accuracy and support clinical application22.

Figure 1. (a) Synchrotron phase contrast imaging (SR-PCI) with 3D orthographic rendering of an intact left
human inner ear. The bony wall of the cochlea was made semi-transparent to permit visualization of the basilar
membrane (BM), Rosenthal’s canal (RC) and auditory nerve (AN). The auditory nerve contains approx. 30,000
fibres and their cell bodies are located in a 14.5 mm long spiral bony canal called RC. From there, peripheral
neurites spread out to innervate approx. 15,000 hair cells placed on the BM. A probe is shown penetrating the
round window (RW) membrane to access the underlying RC. (b) Microradiograph taken following placement
of a radio-opaque marker at the presumed site of RC on anatomical dissection; the image confirms precise
targeting of RC during dissection.

Table 1. The length, diameter and volume of Rosenthal’s Canal (RC) as determined by synchrotron phase-
contrast imaging in the 10 human temporal bones in the study. The diameter of the RC is larger with increasing
distance from the base of the cochlea.

| Bone # | RC length (mm) | RC diameter (mm) | RC volume (mm³) |
|--------|----------------|-----------------|-----------------|
|        | Total          | RC base 45°     | 90°             | Total           |
| 1      | 14.02          | 0.133           | 0.291           | 0.435           | 1.182          |
| 2      | 14.73          | 0.100           | 0.366           | 0.498           | 1.376          |
| 3      | 14.28          | 0.109           | 0.395           | 0.464           | 1.087          |
| 4      | 14.61          | 0.060           | 0.442           | 0.430           | 1.392          |
| 5      | 14.22          | 0.116           | 0.432           | 0.495           | 1.668          |
| 6      | 15.08          | 0.143           | 0.382           | 0.464           | 1.746          |
| 7      | 14.91          | 0.103           | 0.482           | 0.590           | 1.246          |
| 8      | 14.58          | 0.109           | 0.494           | 0.567           | 2.315          |
| 9      | 14.27          | 0.122           | 0.468           | 0.444           | 2.012          |
| 10     | 14.98          | 0.096           | 0.519           | 0.637           | 2.150          |
| Average| 14.568         | 0.109           | 0.427           | 0.502           | 1.617          |
| SD     | 0.36058        | 0.023           | 0.069           | 0.072           | 0.430          |
Material and methods

Ten adult human temporal bones were obtained with permission from the Body Bequeathal Program at Western University, London, Ontario, Canada in accordance with and approved by the Anatomy Act of Ontario and Western University’s Committee for Cadaveric Use in Research (approval #19062014). The imaging technique used in this study is the propagation-based X-ray phase-contrast imaging (PCI) method, which is also known as in-line PCI and has previously been adopted by us to image the auditory system18–20. Compared to conventional X-ray absorption based imaging, in-line PCI uses X-ray refraction which highlights tissue boundaries within a sample. It can be used to image soft tissues which do not absorb X-rays sufficiently to distinguish tissue components based on image contrast. A spatially coherent source is needed for in-line PCI, hence synchrotron radiation is used in this work rather than a conventional X-ray source. The overall set-up for in-line PCI is similar to typical absorption based radiography in that it consists of a source, a sample, and a detector; however, the main difference is that the detector is placed further from the sample when using in-line PCI, and this gives rise to Fresnel fringes. In-line PCI is sensitive to changes in refractive index which leads to edge enhancement in images.

SR-PCI scanning was performed at the Bio-Medical Imaging and Therapy (BMIT) 05ID-2 beamline at the Canadian Light Source Inc. located in Saskatoon, SK, Canada. The X-ray photon energy was 42 keV, with sample-to-source distance of 57 m and sample-to-detector distance of 2 m. The detector had field of view of 36 mm × 9.5 mm and pixel size of 9 µm, and 3000 projections were collected over 180° rotation. The reconstruction was performed using the UFO platform (www.github.com/ufo-kit), which is an open-source platform. To perform the quantitative analysis and 3D visualization, phase-retrieval technique was used to convert the edge enhancement caused by fringes, to areal contrast using Paganin/TIE method21. The reconstructed slices were then imported to 3D Slicer (www.slicer.org) for visualization, segmentation and measurements18–20. Manual threshold
painting was performed for most anatomical structures. Measurements of volumes and distances to adjacent critical structures was then undertaken and trajectory maps for future surgical approaches were designed. Image segmentation was driven by the need to survey the anatomical structures of clinical interest. Semi-automatic and manual segmentation tools, threshold painting, thresholding, tractography, and scissors tools were used to display the fine detail of the structures of interest.

**Ethics approval.** Permission was obtained from the Body Bequeathal Program at Western University, London, Ontario, Canada in accordance with and approved by the Anatomy Act of Ontario and Western University’s Committee for Cadaveric Use in Research (approval #19062014).

**Data availability**

All data generated or analysed during this study are included in this published article and its supplementary information files.

Received: 15 June 2022; Accepted: 11 October 2022

Published online: 08 November 2022

**References**

1. **WHO World Report on Hearing 2021** (2021). [https://www.who.int/publications/i/item/world-report-on-hearing](https://www.who.int/publications/i/item/world-report-on-hearing)
2. Hudspeth, A. J. Integrating the active process of hair cells with cochlear function. *Nat. Rev. Neurosci.* **15**, 600–614 (2014).
3. Liberman, M. C. & Kujawa, S. G. Cochlear synaptopathy in acquired sensorineural hearing loss: Manifestations and mechanisms. *Hear. Res.* **349**, 138–147 (2017).
4. Zhang, T., Dormann, M. E., Gifford, R. & Moore, B. C. J. Cochlear dead regions constrain the benefit of combining acoustic stimulation with electric stimulation. *Ear Hear.* **35**, 410–417 (2014).
5. Furness, D. N. Forgotten fibrocytes: A neglected, supporting cell type of the cochlea with the potential to be an alternative therapeutic target in hearing loss. *Front. Cell. Neurosci.* **19**, 13 (2019).
6. Wilson, B. S., Tucci, D. L., Merson, M. H. & O’Donoghue, G. M. Global hearing health care: New findings and perspectives. *Lancet (Lond., Engl.)* **390**, 2503–2515 (2017).
7. Korver, A. M. H. et al. Congenital hearing loss. *Nat. Rev. Dis. Prim.* **3**, 1 (2017).
8. Chen, W. et al. Restoration of auditory evoked responses by human ES-cell-derived otic progenitors. *Nature* **490**, 278–282 (2012).
9. Buytaert, J., Goyens, J., De Greef, D., Aerts, P. & Dircks, J. Volume shrinkage of bone, brain and muscle tissue in sample preparation for micro-CT and light sheet fluorescence microscopy (LSFM). *Microsc. Microanal.* **20**, 1208–1217 (2014).
10. Schart-Morén, N., Agrawal, S. K., Ladak, H. M., Li, H. & Rask-Andersen, H. Effects of various trajectories on tissue preservation in cochlear implant surgery: A micro-computed tomography and synchrotron radiation phase-contrast imaging study. *Ear Hear.* **40**, 393–400 (2019).
11. Li, H. et al. Vestibular organ and cochlear implantation—a synchrotron and micro-CT study. *Front. Neurol.* **12**, 5 (2021).
12. Lareida, A. et al. High-resolution X-ray tomography of the human inner ear: Synchrotron radiation-based study of nerve fibre bundles, membranes and ganglion cells. *J. Microsc.* **234**, 95–102 (2009).
13. Schart-Morén, N., Larsson, S., Rask-Andersen, H. & Li, H. Three-dimensional analysis of the fundus of the human internal acoustic canal. *Ear Hear.* **39**, 563–572 (2018).
14. Andres-Mateos, E. et al. Choice of vector and surgical approach enables efficient cochlear gene transfer in nonhuman primate. *Nat. Commun.* **13**, 1359 (2022).
15. Lustig, L. & Akil, O. Cochlear gene therapy. *Cold Spring Harb. Perspect. Med.* **9**, 3191 (2019).
16. Crane, R., Conley, S. M., Al-Ubaidi, M. R. & Naash, M. I. Gene therapy to the retina and the cochlea. *Front. Neurosci.* [https://doi.org/10.3389/fnins.2021.652215](https://doi.org/10.3389/fnins.2021.652215) (2021).
17. Plontke, S. K. & Salt, A. N. Local drug delivery to the inner ear: Principles, practice, and future challenges. *Hear. Res.* **368**, 1–2 (2018).
18. Elfarawany, M. et al. Micro-CT versus synchrotron radiation phase contrast imaging of human cochlea. *J. Microsc.* **265**, 349–357 (2017).
19. Koch, R. W., Ladak, H. M., Elfarawany, M. & Agrawal, S. K. Measuring Cochlear Duct Length—a historical analysis of methods and results. *J. Otolaryngol. Head Neck Surg.* **46**, 19 (2017).
20. Mei, X. et al. Vascular supply of the human spiral ganglion: Novel three-dimensional analysis using synchrotron phase-contrast imaging and histology. *Sci. Rep.* [https://doi.org/10.1038/s41598-020-62653-0](https://doi.org/10.1038/s41598-020-62653-0) (2020).
21. Paganin, D., Mayo, S. C., Gureyev, T. E., Miller, P. R. & Wilkins, S. W. Simultaneous phase and amplitude extraction from a single defocussed image of a homogeneous object. *J. Microsc.* **206**, 33–40 (2002).
22. Nikan, S. et al. PWD-3DNet: A deep learning-based fully-automated segmentation of multiple structures on temporal bone Ct scans. *IEEE Trans. Image Process.* **30**, 739–753 (2021).

**Acknowledgements**

The research was funded by a grant from Rinri Therapeutics administered by the University of Nottingham. Part of the research was funded by Swedish Hearing Research Foundation. Part of the research described in this paper was performed at the Canadian Light Source, a national research facility of the University of Saskatchewan, which is supported by the Canada Foundation for Innovation (CFI), the Natural Sciences and Engineering Research Council (NSERC), the National Research Council (NRC), the Canadian Institutes of Health Research (CIHR), the Government of Saskatchewan, and the University of Saskatchewan. We are grateful to Matthew B. Farr for the 3D reconstruction that helped with the preparation of Supplementary Fig. 1 and to Faizah Mushtaq for project administration.

**Author contributions**

Author contributions:Conceptualization: all authors contributed equally Synchrotron imaging: S.A.R., N.Z., S.A., H.M.L. Modelling and Validation: H.L., D.E.H., D.J., G.M.O’D, H.R.A. Writing—original draft: G.M.O’D; Writing-review & editing: all authors contributed equally.
